Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive...
Maev I. V., Samsonov A. A., Palgova L. K., Pavlov Ch. S., Shirokova E. N., Starostin K. M.
BMJ Open Gastroenterology
Vol.6, Issue1, Num.e000307
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1136/bmjgast-2019-000307
Аннотация:
Objective Previous research conducted in Russia showed that the number of patients with non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large. We conducted an observational study to describe the management of NAFLD in patients with metabolic syndrome in Russia. Design A total of 2843 adult patients from 174 medical sites across 6 federal districts of Russia with newly diagnosed NAFLD, who had at least one of four comorbidities, namely overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who received phosphatidylcholine (PPC) as an adjunctive treatment to standard care, were enrolled during 2015-2016. Results Overall, 2263 patients (79.6[%]) had at least two metabolic comorbidities associated with NAFLD; overweight/obesity was the most common comorbidity reported in 2298 patients (80.8[%]). Simple steatosis was the most frequently identified clinical form of NAFLD, diagnosed in 2128 patients (74.9[%]). Among hypertensiv
Ключевые слова:
comorbidities; essential phospholipids; non-alcoholic fatty liver disease; obesity; overweight; phosphatidylcholine; Russia
antilipemic agent; biguanide derivative; cholesterol; dipeptidyl carboxypeptidase inhibitor; fenofibrate; hydroxymethylglutaryl coenzyme A reductase inhibitor; phosphatidylcholine; sartan derivative; adjuvant therapy; adult; Article; cholesterol blood level; chronic liver disease; comorbidity; diabetic patient; fatty liver; female; hepatomegaly; human; hypercholesterolemia; hypertension; major clinical study; male; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; obesity; observational study; patient compliance; patient satisfaction; prescription; prevalence; priority journal; Russian Federation; transient elastography
Язык текста: Английский
ISSN: 2054-4774
Maev I. V.
Samsonov A. A.
Palgova L. K.
Pavlov Ch. S. Chavdar Savov 1967-
Shirokova E. N. Elena Nikolaevna 1965-
Starostin K. M.
Маев И. В.
Самсонов А. А.
Палгова Л. К.
Павлов Ч. С. Чавдар Савов 1967-
Широкова Е. Н. Елена Николаевна 1965-
Старостин К. М.
Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia
Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive...
Текст визуальный непосредственный
BMJ Open Gastroenterology
BMJ Publishing Group
Vol.6, Issue1 Num.e000307
2019
Статья
comorbidities essential phospholipids non-alcoholic fatty liver disease obesity overweight phosphatidylcholine Russia
antilipemic agent biguanide derivative cholesterol dipeptidyl carboxypeptidase inhibitor fenofibrate hydroxymethylglutaryl coenzyme A reductase inhibitor phosphatidylcholine sartan derivative adjuvant therapy adult Article cholesterol blood level chronic liver disease comorbidity diabetic patient fatty liver female hepatomegaly human hypercholesterolemia hypertension major clinical study male non insulin dependent diabetes mellitus nonalcoholic fatty liver obesity observational study patient compliance patient satisfaction prescription prevalence priority journal Russian Federation transient elastography
Objective Previous research conducted in Russia showed that the number of patients with non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large. We conducted an observational study to describe the management of NAFLD in patients with metabolic syndrome in Russia. Design A total of 2843 adult patients from 174 medical sites across 6 federal districts of Russia with newly diagnosed NAFLD, who had at least one of four comorbidities, namely overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who received phosphatidylcholine (PPC) as an adjunctive treatment to standard care, were enrolled during 2015-2016. Results Overall, 2263 patients (79.6[%]) had at least two metabolic comorbidities associated with NAFLD; overweight/obesity was the most common comorbidity reported in 2298 patients (80.8[%]). Simple steatosis was the most frequently identified clinical form of NAFLD, diagnosed in 2128 patients (74.9[%]). Among hypertensiv